» Articles » PMID: 20497720

SH-SY5Y Human Neuroblastoma Cell Line: in Vitro Cell Model of Dopaminergic Neurons in Parkinson's Disease

Overview
Specialty General Medicine
Date 2010 May 26
PMID 20497720
Citations 259
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the human neuroblastoma SH-SY5Y cell line as an in vitro model of dopaminergic (DAergic) neurons for Parkinson's disease (PD) research and to determine the effect of differentiation on this cell model.

Data Sources: The data of this review were selected from the original reports and reviews related to SH-SY5Y cells published in Chinese and foreign journals (Pubmed 1973 to 2009).

Study Selection: After searching the literature, 60 articles were selected to address this review.

Results: The SH-SY5Y cell line has become a popular cell model for PD research because this cell line posses many characteristics of DAergic neurons. For example, these cells express tyrosine hydroxylase and dopamine-beta-hydroxylase, as well as the dopamine transporter. Moreover, this cell line can be differentiated into a functionally mature neuronal phenotype in the presence of various agents. Upon differentiation, SH-SY5Y cells stop proliferating and a constant cell number is subsequently maintained. However, different differentiating agents induce different neuronal phenotypes and biochemical changes. For example, retinoic acid induces differentiation toward a cholinergic neuronal phenotype and increases the susceptibility of SH-SY5Y cells to neurotoxins and neuroprotective agents, whereas treatment with retinoic acid followed by phorbol ester 12-O-tetradecanoylphorbol-13-acetate results in a DAergic neuronal phenotype and decreases the susceptibility of cells to neurotoxins and neuroprotective agents. Some differentiating agents also alter kinetics of 1-methyl-4-phenyl-pyridinium (MPP(+)) uptake, making SH-SY5Y cells more similar to primary mesencephalic neurons.

Conclusions: Differentiated and undifferentiated SH-SY5Y cells have been widely used as a cell model of DAergic neurons for PD research. Some differentiating agents afford SH-SY5Y cells with more potential for studying neurotoxicity and neuroprotection and are thus more relevant to experimental PD research.

Citing Articles

Manuscript title: unravelling the neuroprotective role of miR-27a-3p in the MAPK pathway in Parkinson's disease.

Moradi Vastegani Z, Ghaedi-Heidari R, Oroujalian A, Peymani M, Ghaedi K Metab Brain Dis. 2025; 40(3):141.

PMID: 40067516 DOI: 10.1007/s11011-025-01568-z.


Retinoic Acid Promotes Neuronal Differentiation While Increasing Proteins and Organelles Related to Autophagy.

Lazzeri G, Lenzi P, Signorini G, Raffaelli S, Giammattei E, Natale G Int J Mol Sci. 2025; 26(4).

PMID: 40004155 PMC: 11855701. DOI: 10.3390/ijms26041691.


Network-Based Drug Optimization toward the Treatment of Parkinson's Disease: NRF2, MAO-B, Oxidative Stress, and Chronic Neuroinflammation.

Duarte P, Sanchez-Porro F, Crisman E, Cores A, Jimenez I, Cuadrado A J Med Chem. 2025; 68(3):3495-3517.

PMID: 39818855 PMC: 11881042. DOI: 10.1021/acs.jmedchem.4c02659.


Investigating the therapeutic effects of Shenzhiling oral liquid on Alzheimer's disease: a network pharmacology and experimental approach.

Qin G, Song R, Sun J, Chen B, Liu Z, Han L 3 Biotech. 2024; 15(1):14.

PMID: 39703418 PMC: 11652558. DOI: 10.1007/s13205-024-04181-6.


Dopamine D1-Like Receptor Stimulation Induces CREB, Arc, and BDNF Dynamic Changes in Differentiated SH-SY5Y Cells.

Rivera-Maya O, Ortiz-Robles C, Palacios-Valladares J, Calderon-Aranda E Neurochem Res. 2024; 50(1):35.

PMID: 39601897 PMC: 11602804. DOI: 10.1007/s11064-024-04293-8.